By Adriano Marchese
BeiGene said Wednesday that it has received European regulatory approval for its treatment of gastric and esophageal cancers.
The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.
The oncology company said the approval is based on data from a recent study that met its primary endpoint, resulting in statistically significant and clinically meaningful overall survival benefits compared with placebo plus chemotherapy.
The study found that the median overall survival was for 17.2 months with Tevimbra compared with 10.6 months without.
These two forms of cancers are among the most common cancers and among the most common causes of cancer-related deaths. Nearly a million new patients were diagnosed with gastric cancer in 2022, and 660,000 deaths were reported globally, while close to a million new esophageal cancer cases are projected in 2040, an increase of nearly 60% from 2020, the company said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 27, 2024 06:30 ET (11:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。